Try our beta test site

An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer (FAR-122)

This study has been terminated.
(study did not meet pre-specified criteria for continuation following interim futility analysis)
Information provided by (Responsible Party):
Morphotek Identifier:
First received: August 18, 2008
Last updated: April 24, 2015
Last verified: April 2015

August 18, 2008
April 24, 2015
September 2008
December 2011   (Final data collection date for primary outcome measure)
  • Progression-free survival (PFS) as determined by RECIST [ Time Frame: Length of Study ]
    PFS as determined by RECIST
  • Overall Survival [ Time Frame: Length of study ]
Progression-free survival using GCIG response criteria [ Time Frame: 2 years ]
Complete list of historical versions of study NCT00738699 on Archive Site
  • Progression Free Survival based on Gynecologic Cancer InterGroup(GCIG) [ Time Frame: Length of study ]
    PFS as assessed byt CGIG criteria
  • Overall Response Rate [ Time Frame: Length of study ]
  • Serologic response rate [ Time Frame: Length of study ]
    Serologic response rate assessed by modified Rustin Criteria
  • Safety and tolerability [ Time Frame: Length of Study ]
    Assessed by safety measurements such as review of Adverse events, Vital signs, Physical exams, Electrocardiograms, Clinical labrotory tests, Karnofsky's performance status.
overall response,overall survival and cardiac substudy [ Time Frame: 1 year ]
Not Provided
Not Provided
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
A Randomized, Double Blind, Placebo-Controlled Study of the Efficacy and Safety oF MORAb-003(Farletuzumab) in Combination With Paclitaxel Therapy in Subjects With Platinum-Resistant or Refractory Relapsed Ovarian Cancer
The study is being conducted to find out if paclitaxel works better when given together with an experimental drug called MORAb-003(farletuzumab) or alone in patients with platinum-resistant or refractory relapsed ovarian cancer
Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Ovarian Cancer
  • Drug: MORAb-003 (farletuzumab)
    2.5mg/kg IV day 1 weeks 1-12 (cycle 1); day 1 weeks 1-3 with week 4 as rest week for subsequent cycles
  • Drug: 0.9% Saline
    2.5mg/kg IV day 1 weeks 1-12 (cycle 1); day 1 weeks 1-3 with week 4 as rest week for subsequent cycles
  • Active Comparator: 1
    Paclitaxel with MORAb-003(farletuzumab)
    Intervention: Drug: MORAb-003 (farletuzumab)
  • Placebo Comparator: 2
    Paclitaxel with Placebo
    Intervention: Drug: 0.9% Saline
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
October 2012
December 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of non-mucinous epithelial ovarian cancer, including primary peritoneal and fallopian tube malignancies, measurable by CT or MRI scan assessed within 4 weeks prior to study entry
  • Must have evidence of relapse by CA-125 (2xUpper Limit of Normal) or radiographically within 6 months of most recent platinum-containing chemotherapy. At least one of the lines of chemotherapy must have included a taxane.
  • Must have been treated with debulking surgery and at least one line platinum-based chemotherapy;
  • Subjects may have received up to four additional lines of chemotherapy after they developed platinum-resistance.
  • Subjects must be candidate for repeat paclitaxel treatment

Exclusion Criteria:

  • Clinical contraindications to use of paclitaxel, which include:

    1. persistent Grade 2 or greater peripheral neuropathy
    2. prior hypersensitivity reaction that persisted despite rechallenge with or without desensitization or resulted in bronchospasm or hemodynamic instability or was at least Grade 2 and resulted in medication discontinuation
  • Current diagnosis of epithelial ovarian tumor of low malignant potential (borderline carcinomas). Note: EOC with prior diagnosis of a low malignant potential tumor that has been surgically resected is acceptable provided the subject did
  • Prior radiation therapy is excluded with the exception that it is allowable only if measurable disease for ovarian cancer is completely outside the radiation portal
  • Known allergic reaction to a prior monoclonal antibody therapy or have any documented human anti-human antibody (HAHA).
  • Previous treatment with MORAb-003 (farletuzumab).
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Belgium,   Canada,   Netherlands,   Spain
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP